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Abstract
Purpose: Extracellular matrix metalloproteinase inducer (EMMPRIN) has been shown to stimulate fibroblasts to produc-
tion of matrix metalloproteinases (MMPs). MMPs comprise a family of proteolytic enzymes implicated in the degradation
of extracellular matrix which has been proposed to be one of the essential steps in tumor invasion and metastases. In the
present study we investigated the expression and location of mRNAs for EMMPRIN, matrix metalloproteinase-2 (MMP-2),
and membrane-type 1 matrix metalloproteinase (MT1-MMP) in mesenchymal tumors with different tendencies to recur or
metastasize.
Subjects: Eight malignant fibrous histiocytomas (MFH), seven aggressive fibromatosis (AF), and six benign fibrous tumors
(BF).
Method: The mRNA-expression of EMMPRIN, MMP-2 and MT1-MMP were studied using mRNA in situ hybridization
technique.
Results: The mRNA-expression of EMMPRIN, MMP-2 and MT1-MMP respectively were found at varying frequency and
level in all tumor types. The mRNAs corresponding to EMMPRIN and MMP-2 were seen in neoplastic cells as well as in
endothelial cells both inside and outside the tumor pseudo-capsule, whereas MT1-MMP was seen only within the tumors.
The estimated mRNA levels of EMMPRIN and MMP-2 covariated significantly. Overall, the highest expression was found
in the MFH tumors and the lowest levels in the BF tumors.
Discussion: These findings suggest that the MMP-inducer EMMPRIN and the extracellular matrix degrading system
involving the metalloproteinases MMP-2 and MT1-MMP is frequently activated in mesenchymal tumors. The covariation
between EMMPRIN and MMP-2 support previous findings that EMMPRIN may be an inducer of MMP-2. The high
levels of MMP-2 mRNA in MFH indicate a relationship between the proteolytic activity of MMP-2 and the tumor aggres-
siveness.
Introduction
Soft tissue sarcomas constitute a heterogeneous and
complex group of malignant tumors of mesenchymal
origin which can potentially develop anywhere in the
human body. A multitude of entities are described,
the recognition of which is essential for their proper
treatment and clinical handling. Today, surgery is the
mainstay treatment for all mesenchymal tumors and
there are no other generally applied effective treat-
ments. Although surgery is often extensive, there is a
need for better  complements to the  surgical treat-
ment, and hence a demand for the development of
reliable prognostic markers in the planning of treat-
ment.
The most common type of soft tissue sarcoma is
malignant  fibrous  histiocytoma  (MFH),  which
accounts for  25–40%  of  all  cases in adulthood.1,2
This entity is generally characterized by aggressive
biological  behaviour,  and  the  patients  frequently
develop distant metastases and local recurrence. The
majority of cases are of high malignancy grade (grade
3 or 4 on a four-grade scale,3–4) and the reported 5-
year survival rates vary between 50% and 70%.5–7
Today the most important prognostic factors include
tumor  size,  localization  and  histopathological
grade.1–4 The value of molecular assays has become
evident to improve diagnostic sensitivity and speci-
ficity, and to achieve an improved understanding of
the  molecular  mechanisms  involved  in  the  tumor144 J. Åhlén et al.
development and progression. Aggressive fibromato-
sis (AF) is a fibrous tissue tumor that usually occurs
in the subfascial tissue of the abdominal wall, shoul-
der  or  chest  wall.  It  never  metastasizes  but  local
recurrence  is  often  seen  after  surgical  excision.
Benign fibrous tumors (BF) usually develop in the
subcutaneous  tissue  or  tendon  sheath  but  rarely
recur and never metastasize.
Interactions  between  the  tumor  cells  and  the
stroma leading to degradation of the basement mem-
brane  and  the  stromal  extracellular  matrix  play
important roles in the  metastatic  process of  many
types of tumors. Matrix metalloproteinase-2 (MMP-
2,  72kDa  type  IV  collagenase,  Gelatinase  A)  and
membrane-type 1 matrix metalloproteinase (MT1-
MMP), are members of a family of zinc-dependent
proteolytic enzymes that degrade extracellular matrix
proteins,  glycoproteins  and  proteoglycans  and  are
implicated in the extracellular matrix (ECM) remod-
elling  and  degradation  processes.8,9  MMP-2
degrades type  IV  collagen which  is  unique to  the
basement membrane, and has thus been shown to be
of  importance  for  tumor  cell  invasion  and
metastases.10,11 It is secreted as a latent pro-enzyme
which is activated on the cell surface by a complex
consisting of MT1-MMP, a metalloproteinase with a
transmembrane domain,12  and  tissue  inhibitors  of
metalloproteinase type 2 (TIMP-2), a natural inhibi-
tor of MMPs.13 EMMPRIN is a transmembrane gly-
coprotein  belonging  to  the  superfamily  of
immunoglobulins. It  is  attached  to  the  surface  of
many  types  of  malignant  human  tumor  cells.14,15
EMMPRIN has been shown to stimulate fibroblasts
to produce MMPs and is thus proposed to regulate
the MMP production during tumor invasion.16–18
The purpose of this study was to investigate the
involvement of these genes by measuring the mRNA
expression of EMMPRIN, MMP-2, and MT1-MMP
in mesenchymal tumors with different clinical out-
come and with different tendency to recur or metas-
tasize.
Patients and tumor material
The 21 patients were all operated on at the Karolin-
ska Hospital, and none of the patients had received
any postoperative treatment. Patient and tumor data
are given in Table 1. All tumors were re-evaluated
and classified, according to established histopatho-
logical criteria,1 by an experienced histopathologist
who had no knowledge of the clinical course. The
malignancy grading was determined on a four-grade
scale based on the estimation of cellularity, cellular
atypia, necrosis and mitotic frequency.3,4 The surgi-
cal  margins  were  also  re-evaluated.  The  study
included eight cases with MFH (four storiform-pleo-
morphic, two myxoid and two giant cell type), seven
cases of aggressive fibromatosis (AF), and six benign
fibrous tumors (BF) (two fibrous histiocytomas and
four  fibromas  of  the  tendon  sheath).  All  MFH
patients were operated on in 1990, and those with AF
or BF were operated on between 1990 and 1995.
Methods
RNA probe preparation
For RNA preparation of antisense and sense probes
full length cDNA of EMMPRIN (1.6 kb) and MMP-
2 (1.2 kb) were subcloned into bluescript transcrip-
tion vectors. The constructs were linearized with the
proper restriction enzymes for RNA probe transcrip-
tion.  An  MT1-MMP  cDNA  fragment  (nt
1647–2889) was subcloned into the pGEM 4 vector,
and antisense (405bp)  and  sense (837  bp)  probes
were transcribed. The transcriptional products were
designed to eliminate the risk of cross-reactivity. The
cDNA plasmids were generously supplied by Huim-
ing Guo, Tufts University, Boston, Massachusetts,
USA (EMMPRIN),16 Gregory I. Goldberg, Wash-
ington University, St. Louis, MO, USA (MMP-2)19
and Hiroshi Sato,  Kanazawa  University, Ishikawa,
Japan (MT1-MMP).12 The sense RNA probes were
used as internal negative controls for each hybridiza-
tion reaction. Hybridization to adrenocortical cancer
tissue  was  used  as  a  positive  control  for  the
EMMPRIN  probe,  and  to  breast  carcinomas  for
MMP-2 and MT1-MMP. In addition hybridization
with a  -actin probe was used as a positive control of
RNA  presence  in  all  tumors.  In  vitro  transcribed
RNA was labelled with 35S-UTP (10mCi/ml) using
the  conditions  and  reagents  recommended by  the
manufacturer (Promega, Madison WI,  USA),  and
purified by ultrafiltration  (Microcon 100,  Amicon,
Beverly, MA, USA) prior to the hybridization reac-
tions.
RNA in situ hybridization
The hybridization procedures used in this study were
essentially  as  previously  described.20  Paraffin-
embedded sections of 5 µm were deparaffinized with
limonene,  rehydrated  through  graded  ethanol  fol-
lowed by phosphate buffered saline at room temper-
ature (RT), treated with proteinase-K (1 µg/ml, 30
minutes, 37ºC), and then treated for 10 minutes with
0.1  M  triethanolamine buffer (pH  8.0)  containing
0.25% acetic anhydride to reduce background. The
sections were then washed twice in 2× SSC, dehy-
drated in graded ethanol,  air dried, and heated to
60ºC  for  30  minutes.  The  hybridization  solution
(HS) containing 50% formamide, 2× SSC, 20mM
Tris-HCl pH  8.0,  1×  Denhardt’s  solution, 1  mM
EDTA, 10% dextran sulfate, yeast tRNA 500µg/ml
mixed with 100mM dithiothreitol (DDT), and 2.5 ×
103–4 cpm/µl 35S-labeled RNA probe was preheated
to 68ºC for 10 minutes and cooled down to RT on
ice. The tumor sections were covered with HS, and
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ber. After hybridization, stringent washing was per-
formed  with  SSC  and  10mM  DDT,  the  most
stringent  step  being  0.1×  SSC  for  15  minutes  at
60ºC. Non-specific binding was reduced by incubat-
ing the sections in RNAse buffer (0.5 M NaCl, 10
mM Tris-HCl pH 8.0, 1 mM EDTA) and RNAse A
(20  µg/ml)  for  30  minutes  at  37ºC  followed  by
washes with RNAse buffer and SSC in decreasing
concentrations, the last two steps consisting of 0.1×
SSC for 15 minutes at 60ºC and for 30 minutes at
RT. The sections were then dehydrated in ethanol,
air dried, dipped in Kodak NTB-2 emulsion, exposed
for 5–12 days (MMP-2), 5–13 days (EMMPRIN),
and 6–38 days (MT1-MMP) respectively, developed,
and  counter-stained  with  hematoxylin-eosin.  The
sections were evaluated with both light and darkfield
microscopy. Evaluation of the hybridization results
were  performed by  three  investigators  including a
pathologist who also re-evaluated the histopathologi-
cal diagnosis. In the evaluation of MT1-MMP, five of
the 21 tumors had positive signals for the sense probe
and  were  therefore  excluded.  The  expression  of
mRNA was graded as – = no expression above back-
ground; + = low, low expression in few cells (<10%);
++ = moderate, moderate to high expression in many
cells (10–70%); and +++ = high, high expression in
the  majority of  cells or in all  cells (>70%)  (Table
2–4). The classification was based on the areas with
the most pronounced expression and examples of the
scoring are illustrated in Figure 1.
Statistical analyses
The relationship between high mRNA-expression of
EMMPRIN, MMP-2 or MT1-MMP and tumor type
was analysed using the Fisher’s exact test. The asso-
ciation between high mRNA levels and clinical out-
come in MFH patients was analysed using Kaplan-
Meier log-rank survival curves and Log-Rank test to
evaluate the difference between the curves. The cor-
relation between EMMPRIN and MMP-2 was ana-
lysed using Spearman Rank order. All analyses where
made in STATISTICA 5.5 software. Probabilities of
<0.05 were accepted as statistically significant.
Results
The mRNA-expression of EMMPRIN, MMP-2 and
MT1-MMP were analysed in twenty-one mesenchy-
mal tumors by mRNA in situ hybridization technique.
The clinical data,  outcome and histopathology are
given for each case in Table 1. Three of the eight
patients with MFH died of the disease during follow-
up. One patient had a local recurrence which was
treated surgically, he has thereafter no evidence of
disease at 6 years follow-up (Case no. 4, Table 1).
The remaining four patients with MFH were without
any evidence of the disease after a mean follow up of
7.5  years.  The  mean  follow-up  for  the  seven  AF
patients was 4 years during which one of the tumors
recurred locally (Case no. 13, Table 1). None of the
six BF recurred (Table 1).
Table 1. Clinical data for the 21 mesenchymal tumors in the study
Case no.
Age/
sex Diagnosis
Histologic 
Subtype
Grade
(1–4) Localisation
Surgical 
margin Metastases
Local
rec. Outcome
Follow up 
(months)
  1 40/M MFH SP 3 Lower extr Intralesional yes no DOD 9
  2 74/F MFH SP 3 Lower extr Wide yes no DOD 61
  3 69/F MFH myxoid 3 Upper extr Wide yes no DOD 57
  4 67/M MFH GC 4 Upper extr Wide no yes* NED 75
  5 76/M MFH SP 4 Lower extr Wide no no NED 81
  6 69/F MFH SP 3 Shoulder Wide no no NED 89
  7 51/M MFH myxoid 1 Lower extr Wide no no NED 91
  8 25/F MFH GC 3 Upper extr Marginal no no NED 98
  9 35/F AF – Trunk wall Marginal no no NED 60
10 26/M AF – Shoulder Marginal no no NED 36
11 49/F AF – Shoulder Intralesional no no NED 36
12 46/F AF – Lower extr. Marginal no no NED 12
13 40/M AF – Shoulder Marginal no yes NED 96
14 33/F AF – Thoracic wall Intralesional no no NED 60
15 52/F AF – Shoulder Wide no no NED 60
16 63/M BF FT – Knee Marginal no no NED 96
17 65/F BF FH – Neck Marginal no no NED 60
18 39/M BF FT – Hand Marginal no no NED 84
19 27/M BF FT – Thumb Marginal no no NED 120
20 44/F BF FT – Finger Marginal no no NED 96
21 28/F BF FH – Thigh Marginal no no NED 96
*Local recurrence after 11 months, thereafter no signs if diseases. MFH = malignant fibrous histiocytoma; AF = aggressive
fibromatosis; BF = benign fibrous tumor; SP = storiform-pleomorphic; GC = giant cell type; FH = fibrous histiocytoma; FT
= fibroma of tendon sheath; NED = no evidence of disease; DOD = dead of disease.146 J. Åhlén et al.
The results from the mRNA in situ hybridization
are detailed in Table 2.  -actin was used as positive
control and was expressed in all 21 tumors analysed.
Expression of both EMMPRIN, MMP-2, and MT1-
MMP-mRNA, were found at varying frequencies and
levels  in  all  tumor  types.  Expression  was  most
Fig. 1. mRNA in situ hybrization analyses showing expression of EMMPRIN in case no 7 (a1, a2) and case no 5 (b1, b2), and of 
EMMPRIN, MMP-2, MT1-MMP in case no 4 (c1, c2, d1, d2, e1, e2). Hybridization with sense probe were used as negative controls 
(a3–e3). The hybridization signals appear as white spots in dark field microscopy (a1–e1, a3–e3) and as black spots in light field 
microscopy (a2–e2). The scoring of the expression is according to Table 2, and the magnification was ×200.EMMPRIN, MMP-2 and MT1-MMP in mesenchymal tumors 147
commonly  seen  in  the  MFH  tumors,  where
EMMPRIN  mRNA was  expressed in seven of  the
eight cases. MMP-2 mRNA was expressed in all eight
cases and MT1-MMP mRNA was expressed in all six
tumors  that  not  had  positive  sense.  The  levels  of
expression were also comparatively high in the MFH
tumors,  with  high  expression  (+++)  detected  for
EMMPRIN  mRNA  in  4/8  cases  and  for  MMP-2
mRNA in 6/8 cases. No correlation could be seen
between  expression  levels  and  the  different  histo-
pathological subtypes. In the AF tumors EMMPRIN
and MMP-2 were detected in six of the seven cases,
and in three and four cases respectively the detected
level of expression was high (+++). MT1-MMP was
only expressed at low levels (+) in AF. Overall the
lowest levels of expression were seen in BF where
expression of EMMPRIN and MMP-2 were seen in
three and of MT1-MMP in two of the six tumors.
For all three types of tumors the mRNA expres-
sion of EMMPRIN and MMP-2 showed a significant
tendency  to  covariate  (correlation  coefficient  =
0.805,  p<0.001).  This  was  illustrated  by  e.g.  the
high expression (+++) in MFH cases 1–4 and AF
cases 9–11  in which both genes were expressed at
high levels (+++). Similarly BF tumors no 16–18 all
expressed  EMMPRIN  and  MMP-2  mRNA,  while
the  other  three  BF  cases  were  negative  for  both
genes.
EMMPRIN-,  MMP-2-  and  MT1-MMP  mRNAs
were all  identified in neoplastic cells. EMMPRIN-
and  MMP-2  mRNAs  but  not  MT1-MMP  mRNA
were  also  seen  in  endothelial  cells.  The  level  of
expression in endothelial cells was almost identical to
the overall expression. In some of the MFH tumors,
an intratumoral variation of expression was found.
Where normal tissue could be identified outside the
tumor  pseudo-capsule,  EMMPRIN-  and  MMP-2
mRNA were commonly expressed in stroma-like cells
as well as in endothelial cells. Unlike EMMPRIN and
MMP-2, expression of MT1-MMP mRNA was never
seen outside the pseudo-capsule. No mRNA-expres-
sion  of  EMMPRIN,  MMP-2  or  MT1-MMP  was
detected in muscle cells or in adipose tissue outside
the tumor pseudo-capsule.
When  high  tumor  mRNA-expression  of
EMMPRIN, MMP-2 or MT1-MMP were compared
with clinical outcome and tumor type some statisti-
cally  significant  associations  were  revealed.  High
levels of MMP-2 were detected in six of the eight
MFH tumors as compared to none of the BF cases (p
= 0.022).  Similarly when combining the groups of
MFH and AF, which are both characterized by a ten-
dency  to  recur  locally,  high  mRNA-expression of
MMP-2 was seen in ten of the fifteen cases as com-
pared to none of the six BF cases (p=0.008, Table 3).
Furthermore the four MFH patients who died from
the  disease  or  who  developed  a  local  recurrence
during  followup  all  had  high  expression  of
EMMPRIN while this was not the case for any of the
four MFH patients who remained disease free during
Table 2. Results from the mRNA in situ hybridisation analyses
Case no. Type Outcome
mRNA expression of
EMMPRIN MMP-2 MT1-MMP
  1 MFH DOD +++ +++ PS
  2 MFH DOD +++ +++ ++
  3 MFH DOD +++ +++ PS
  4 MFH NED* +++ +++ +++
  5 MFH NED ++ +++ ++
  6 MFH NED ++ +++ +
  7 MFH NED + ++ +
  8 MFH NED - ++ PS
  9 AF NED +++ +++ +
10 AF NED +++ +++ +
11 AF NED +++ +++ +
12 AF NED ++ +++ -
13 AF NED* - + +
14 AF NED + + PS
15 AF NED + - -
16 BF NED +++ ++ -
17 BF NED ++ + PS
18 BF NED ++ ++ ++
19 BF NED - - ++
20 BF NED - - -
21 BF NED - - -
MFH = malignant fibrous histiocytoma; AF = aggressive fibromatosis; BF = benign fibroma;
DOD = dead of disease; NED = no evidence of disease; – = no expression above background;
+ = expression in few cells, <10%; ++ = expression in many cells, 10–70%;
+++ = expression in the majority of cells, >70%; PS = positive sense
*Case no. 4 and 13 have had local recurrence148 J. Åhlén et al.
follow up. This association was also statistically sig-
nificant (p=0.014, Table 4).
Discussion
A major characteristic of the malignant phenotype is
the ability to invade the surrounding stroma and sub-
sequently to metastasize. These events require degra-
dation  of  the  basement  membrane  and  of  the
components of the extracellular matrix. Several met-
alloproteinases and their regulators have previously
been shown to play important roles in the invasion
process of various tumors.21 In the present study the
mRNA-expression  of  EMMPRIN,  MMP-2  and
MT1-MMP were demonstrated in three types of mes-
enchymal tumors with different biological behaviour,
indicating that  the matrix degrading system is  fre-
quently  activated  in  these  tumors.  In  general, the
detection  of  mRNA  expression  for  a  given  gene
cannot be taken as an evidence of a corresponding
protein expression. However, the high expression of
MMP-2 mRNA in MFH and AF is in agreement with
previous reports where a strong immunohistochemi-
cal reactivity for MMP-2 was found in the same type
of tumors.22,24 A significant correlation between the
expression of MMP-2- and MT1-MMP mRNA and
localisation of the corresponding antibodies as dem-
onstrated  by  immunohistochemistry has  also  been
demonstrated  in  head  and  neck  tumors.23  These
findings indirectly  indicate  that  the  production of
mRNA de facto corresponds to a synthesis of the cor-
responding proteins.
The  coexpression  of  EMMPRIN-  and  MMP-2
mRNAs in the majority of the tumors suggests that
EMMPRIN could be of importance for the initiating
of MMP-2 production also in mesenchymal tumors.
We  found  in  agreement  with  previous  reports  for
MMP-2, but not for EMMPRIN, an mRNA expres-
sion in stroma-like and endothelial cells as well as in
neoplastic  cells which  might  reflect their  common
mesenchymal origin.21 EMMPRIN mRNA has previ-
ously been demonstrated in both malignant and non-
cancerous cells e.g. keratocytes. MMP-2 expression
in both benign and malignant cells as has been dem-
onstrated in head and neck carcinoma which  may
represent one of the mesenchymal characteristics that
are  acquired during the  malignant  transformation.
These preliminary data with regard to mesenchymal
tumors should be interpreted with caution consider-
ing  the  difficulty  to  distinguish  between  normal
stroma cells such as fibroblasts and atypical cells that
are frequently seen outside the tumor pseudo-cap-
sule.
A  correlation  between  MMP  production  and
tumor characteristics such as invasiveness and meta-
static  capacity  has  earlier  been  shown  in  several
reports.13 In the present study the mRNA-expression
of MMP-2 was significantly more frequent in MFH
and AF than in BF. Although both BF and AF lack
metastatic potential they frequently expressed MMP-
2 mRNA, indicating that MMP-2 itself is not an indi-
cator  of  metastases.  However,  the  limited  tumor
material in the present study does not allow any con-
clusions to be drawn regarding the role of MMP-2 in
the process of tumor progression.
All tumors from MFH patients who had a local
recurrence or died of the disease, demonstrated high
levels  of EMMPRIN  mRNA whereas this was  not
seen in any of the tumors from patients that remained
disease-free. The role of EMMPRIN as a prognostic
marker in MFH remains to be elucidated. These pre-
liminary  findings  are  in  agreement  with  previous
reports and indicate that activation of the extracellu-
lar matrix degrading system could be an important
component  in  the  aggressive  behaviour  of  MFH
tumors.13
Table 3. High expression (+++, >70% positive cells) of mRNAs in relation to tumor type
Subtype EMMPRIN p-value* MMP-2 p-value* MT1-MMP p-value*
MFH 4/8 (50%) n.s 6/8 (75%) 0.022 1/5 (20%) n.s
AF 3/7 (43%) n.s 4/7 (57%) n.s 0/6 (0%) n.s
MFH+AF 7/15 (47%) n.s 10/15 (67%) 0.008 1/11 (9%) n.s
BF 1/6 (17%) n.s 0/6 (0%) n.s 0/5 (0%) n.s
Total (MFH + AF+BF) 8/21 (38%) 10/21 (48%) 1/16 (6%)
MFH = malignant fibrous histiocytoma; AF = aggressive fibromatosis; BF = benign fibrous tumor
*P-value is calculated as compared to BF; n.s. = not significant
Table 4. MFH tumors with high expression (+++, >70% positive cells) of EMMPRIN-, 
MMP-2- or MT1-MMP-mRNA in relation to clinical outcome
DOD or local rec. NED p-value
EMMPRIN 4/4 (100%) 0/4 (0%) 0.0143
MMP-2 4/4 (100%) 2/4 (50%) n.s
MT1-MMP 1/2 (50%) 0/3 (0%) n.s
DOD = dead of disease; NED = no evidence of disease; n.s = not significantEMMPRIN, MMP-2 and MT1-MMP in mesenchymal tumors 149
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